EMA committee recommends drug candidate from Ascendis Pharma

In the US, the FDA rejected the drug candidate TransCon PTH in May, but in Europe, the path now seems clear for the Danish-American biotech company’s hypoparathyroidism drug to be approved.
EMA’s rådgivende panel, CHMP, anbefaler at godkende lægemiddelkandidaten Transcon PTH, som det dansk-amerikanske biotekfirma Ascendis Pharma står bag. | Photo: Kevin Grønnemann / Medwatch
EMA’s rådgivende panel, CHMP, anbefaler at godkende lægemiddelkandidaten Transcon PTH, som det dansk-amerikanske biotekfirma Ascendis Pharma står bag. | Photo: Kevin Grønnemann / Medwatch

The European Medicines Agency’s (EMA) advisory panel, CHMP, recommends approval of drug candidate TransCon PTH (palopegteriparatide), developed by Danish-American biotech company Ascendis Pharma, the company writes in an announcement on Friday morning.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading